As Sarepta Therapeu (SRPT) Share Value Rose, Marshall Wace Llp Has Cut Holding; Blume Capital Management Has Cut Its Qualcomm (QCOM) Position as Market Valuation Declined

April 23, 2018 - By Peter Erickson

QUALCOMM Incorporated (NASDAQ:QCOM) Logo

Blume Capital Management Inc decreased its stake in Qualcomm Inc (QCOM) by 7.73% based on its latest 2017Q4 regulatory filing with the SEC. Blume Capital Management Inc sold 6,475 shares as the company’s stock declined 15.28% with the market. The institutional investor held 77,335 shares of the radio and television broadcasting and communications equipment company at the end of 2017Q4, valued at $4.95 million, down from 83,810 at the end of the previous reported quarter. Blume Capital Management Inc who had been investing in Qualcomm Inc for a number of months, seems to be less bullish one the $76.15 billion market cap company. The stock decreased 2.15% or $1.13 during the last trading session, reaching $51.44. About 10.81M shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 3.21% since April 23, 2017 and is downtrending. It has underperformed by 14.76% the S&P500.

Paul Marshall decreased its stake in Sarepta Therapeu (SRPT) by 77.91% based on its latest 2017Q4 regulatory filing with the SEC. Marshall Wace Llp sold 21,670 shares as the company’s stock rose 36.45% while stock markets declined. The hedge fund run by Paul Marshall held 6,143 shares of the health care company at the end of 2017Q4, valued at $342,000, down from 27,813 at the end of the previous reported quarter. Marshall Wace Llp who had been investing in Sarepta Therapeu for a number of months, seems to be less bullish one the $5.20 billion market cap company. The stock increased 1.83% or $1.44 during the last trading session, reaching $79.99. About 1.30M shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 23, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Blume Capital Management Inc, which manages about $302.15M and $195.35M US Long portfolio, upped its stake in Tjx Companies Inc. (NYSE:TJX) by 15,325 shares to 39,980 shares, valued at $3.06M in 2017Q4, according to the filing. It also increased its holding in Ishares Biotech Fund (IBB) by 48,519 shares in the quarter, for a total of 72,891 shares, and has risen its stake in Schlumberger (NYSE:SLB).

Analysts await QUALCOMM Incorporated (NASDAQ:QCOM) to report earnings on April, 25 after the close. They expect $0.55 EPS, down 54.17% or $0.65 from last year’s $1.2 per share. QCOM’s profit will be $814.20M for 23.38 P/E if the $0.55 EPS becomes a reality. After $0.85 actual EPS reported by QUALCOMM Incorporated for the previous quarter, Wall Street now forecasts -35.29% negative EPS growth.

Among 37 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 16 have Buy rating, 2 Sell and 19 Hold. Therefore 43% are positive. Qualcomm Inc. had 145 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) has “Neutral” rating given on Tuesday, September 6 by Mizuho. Cowen & Co maintained QUALCOMM Incorporated (NASDAQ:QCOM) on Thursday, July 21 with “Outperform” rating. Cowen & Co maintained the stock with “Outperform” rating in Thursday, November 5 report. Stifel Nicolaus maintained it with “Buy” rating and $59 target in Thursday, November 19 report. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) earned “Hold” rating by Wells Fargo on Monday, November 6. The rating was maintained by Susquehanna with “Buy” on Thursday, June 15. The rating was maintained by Raymond James with “Hold” on Thursday, July 20. On Friday, September 30 the stock rating was maintained by Cowen & Co with “Outperform”. The rating was downgraded by Barclays Capital to “Equal-Weight” on Monday, March 28. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) has “Buy” rating given on Monday, March 26 by Susquehanna.

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.02, from 0.85 in 2017Q3. It turned negative, as 89 investors sold QCOM shares while 518 reduced holdings. 160 funds opened positions while 346 raised stakes. 1.11 billion shares or 0.73% more from 1.10 billion shares in 2017Q3 were reported. Jag Cap Ltd Liability Corp stated it has 0.25% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Park National Corporation Oh has invested 0.04% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Hsbc Hldgs Public Limited owns 3.39M shares. Limited Ca invested in 123,622 shares. 1.50M were accumulated by State Of New Jersey Common Pension Fund D. Edgar Lomax Company Va owns 1.23% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 281,485 shares. Alps Advisors reported 0.33% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Fragasso Grp Inc Inc invested 0.39% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Oakworth Incorporated stated it has 0.1% in QUALCOMM Incorporated (NASDAQ:QCOM). Thrivent Financial For Lutherans holds 69,114 shares or 0.01% of its portfolio. Balyasny Asset Mngmt Ltd Liability Corp accumulated 127,449 shares. Schwab Charles Mngmt accumulated 7.95 million shares. Moreover, Fukoku Mutual Life Ins Communication has 0.06% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 5,960 shares. Ahl Prtnrs Limited Liability Partnership has invested 0.02% in QUALCOMM Incorporated (NASDAQ:QCOM). Security National Tru reported 10,615 shares.

Since October 27, 2017, it had 0 insider buys, and 6 selling transactions for $6.14 million activity. 50,126 QUALCOMM Incorporated (NASDAQ:QCOM) shares with value of $3.14 million were sold by THOMPSON JAMES H. $2.81M worth of QUALCOMM Incorporated (NASDAQ:QCOM) shares were sold by GROB MATTHEW S.

Marshall Wace Llp, which manages about $2.38B US Long portfolio, upped its stake in Sina Corp (NASDAQ:SINA) by 30,084 shares to 66,355 shares, valued at $6.66 million in 2017Q4, according to the filing. It also increased its holding in Biogen Inc (NASDAQ:BIIB) by 11,946 shares in the quarter, for a total of 20,356 shares, and has risen its stake in Halliburton Co (NYSE:HAL).

Investors sentiment decreased to 1.22 in Q4 2017. Its down 1.66, from 2.88 in 2017Q3. It dived, as 27 investors sold SRPT shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported. Raymond James Financial Serv invested in 0.01% or 18,639 shares. Lpl Financial Limited Company holds 11,559 shares or 0% of its portfolio. Glenmede Trust Na has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). North Star Investment Management Corp accumulated 735 shares. Zacks Investment Management has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Federated Pa invested in 48,909 shares or 0.01% of the stock. Mufg Americas Hldgs Corp owns 290 shares for 0% of their portfolio. Quantitative Inv Mgmt Limited Liability Company reported 0.06% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). First Allied Advisory Svcs invested in 0.02% or 9,041 shares. Tower Research Ltd Llc (Trc) stated it has 61 shares. Legal & General Group Inc Public Limited, a United Kingdom-based fund reported 26,363 shares. Castleark Mngmt Limited Liability Co has invested 0.47% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 134,314 were reported by Pnc Fincl Serv Group Inc. Dekabank Deutsche Girozentrale owns 24,733 shares or 0.01% of their US portfolio. Fred Alger Mngmt Inc owns 1.58M shares or 0.4% of their US portfolio.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>